Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03094611
Other study ID # 2015-0870
Secondary ID NCI-2018-0123720
Status Terminated
Phase Phase 2
First received
Last updated
Start date November 30, 2017
Est. completion date March 11, 2020

Study information

Verified date March 2021
Source M.D. Anderson Cancer Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This phase II trial studies how well inotuzumab ozogamicin works in treating patients with CD22 positive acute lymphoblastic leukemia that has come back or does not respond to treatment. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a toxic agent called ozogamicin. Inotuzumab attaches to CD22 positive cancer cells in a targeted way and delivers ozogamicin to kill them.


Description:

PRIMARY OBJECTIVES: I. To evaluate the objective response rate of low dose of inotuzumab ozogamicin as measured by the hematologic remission rate (complete remission [CR] + CR with incomplete platelet recovery [CRp] + CR with incomplete bone marrow recovery [CRi]) in patients in first, second or later salvage setting. SECONDARY OBJECTIVES: I. To evaluate the overall safety profile and the efficacy; the efficacy is measured by the hematologic response rate (CR + CRi + PR), durations of response (DoR) and remission (DoR1), progression free survival (PFS), and overall survival (OS). OUTLINE: Patients receive inotuzumab ozogamicin intravenously (IV) over 1 hour on days 1, 8 and 15 of cycle 1 and on days 1 and 8 beginning cycle 2. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients whose disease gets worse after responding for 3 months, may be retreated for up to 6 additional cycles. Patients whose disease responds to treatment may receive up to 5 additional cycles.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date March 11, 2020
Est. primary completion date March 11, 2020
Accepts healthy volunteers No
Gender All
Age group 12 Years and older
Eligibility Inclusion Criteria: - Patients at least 12 years of age - Patients with a diagnosis of CD22-positive acute lymphoblastic leukemia (ALL) based on local immunophenotyping and histopathology who have: - Refractory disease, defined as disease progression or no response while receiving their most recent prior anti-cancer therapy, - Relapsed disease, defined as response to their most recent prior anti-cancer therapy with subsequent relapse - Performance status of 0 to 3 - Serum creatinine =< 2 x upper limit of normal (ULN) or estimated creatinine clearance >= 15 mL/min as calculated using the method standard for the institution - Total serum bilirubin =< 1.5 x ULN unless the patient has documented Gilbert syndrome. If organ function abnormalities are considered due to tumor, total serum bilirubin must be =< 2 x ULN - Aspartate and alanine aminotransferase (AST or ALT) =< 2.5 x ULN - No active or co-existing malignancy requiring chemotherapy or radiation within 6 months - Female subjects of childbearing potential should be willing to use effective methods birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year. Effective methods of birth control include birth control pills or injections, intrauterine devices (IUDs), or double-barrier methods (for example, a condom in combination with spermicide) - Male subjects should agree to use an effective method of contraception starting with the first dose of study therapy through the duration of treatment Exclusion Criteria: - Pregnant or nursing women - Known to be human immunodeficiency virus (HIV)+ - Philadelphia chromosome (Ph)+ ALL - Active and uncontrolled disease/infection as judged by the treating physician - Unable or unwilling to sign the consent form - Prior allogeneic stem cell transplantation (ASCT) or other anti-CD22 immunotherapy within =< 4 months before first dose of study treatment - Active central nervous system (CNS) or extramedullary disease unless approved by the principal investigator (PI) - Monoclonal antibodies therapy within 2 weeks before study entry - Radiotherapy and cancer chemotherapy (except for intrathecal chemotherapy, hydroxyurea, and cytarabine. Cytarabine and hydroxyurea are allowed to be used emergently in case of leukocytosis) or any investigational drug within 2 weeks before study entry - Evidence or history of veno-occlusive disease (VOD) or sinusoidal obstruction syndrome (SOS)

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Inotuzumab Ozogamicin
Given IV

Locations

Country Name City State
United States M D Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
M.D. Anderson Cancer Center National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants to Achieve Complete Remission (CR) Complete Remission (CR) is the normalization of the peripheral blood and bone marrow with Up to 2 years
Secondary Participants With a Grade 3 or 4 Non-hematologic Adverse Event (AE) For the purpose of toxicity monitoring, toxicities are defined as any treatment -related grade 3 or 4 non-hematologic AEs occurred any time during the trial.NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 utilized for adverse event reporting. Up to 2 years
Secondary Duration of Response The date of Complete Response to the date of loss of response or last follow-up. Up to 3 years
Secondary Progression Free Survival Time from date of treatment start until the date of first objective documentation of disease-relapse. Up to 3 years
Secondary Overall Survival Time from date of treatment start until date of death due to any cause or last Follow-up. Up to 3 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03620058 - CART22 Alone or in Combination With huCART19 for ALL Phase 1
Completed NCT02551718 - High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia N/A
Recruiting NCT04888442 - Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL Phase 1
Suspended NCT03128034 - 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia Phase 1/Phase 2
Withdrawn NCT03739606 - Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Phase 2
Recruiting NCT03241940 - Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies Phase 1
Active, not recruiting NCT02146924 - Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia Phase 1
Recruiting NCT04000698 - Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias Phase 3
Completed NCT03096782 - Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Phase 2
Completed NCT03575325 - Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia Phase 2
Completed NCT04888468 - Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents Phase 1
Recruiting NCT02392572 - ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome Phase 1/Phase 2
Recruiting NCT03263572 - Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positive, or BCR-ABL Positive, or Relapsed/Refractory, Acute Lymphoblastic Leukemia Phase 2
Terminated NCT03519984 - EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Phase 1
Completed NCT04562792 - Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia Phase 2
Active, not recruiting NCT01619761 - NK Cells in Cord Blood Transplantation Phase 1
Completed NCT01865617 - Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia Phase 1/Phase 2
Recruiting NCT02727803 - Personalized NK Cell Therapy in CBT Phase 2
Terminated NCT01620216 - Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia Phase 2
Recruiting NCT04340167 - Study of Anti-CD22 CAR-T Cells Treating Leukemia Children Phase 2